Who Can Take Alyftrek for Cystic Fibrosis?
The original FDA indication covered people age six and older with cystic fibrosis who had at least one F508del mutation or another CFTR mutation shown to respond to the medicine.
Timeline
- December 20, 2024: FDA originally approved Alyftrek for eligible people with cystic fibrosis age six and older.
- 2024: FDA listed Alyftrek among 50 novel drugs approved by its Center for Drug Evaluation and Research that year.
- Original approval: The approved population required at least one F508del or another responsive CFTR mutation.
Under its original U.S. approval, Alyftrek was indicated for people with cystic fibrosis who were at least six years old and had at least one F508del mutation or another responsive mutation in the CFTR gene. The two-part test matters: a patient needed to meet the age requirement and have a genotype covered by the prescribing information. [1][2]
Alyftrek combines three active ingredients: vanzacaftor, tezacaftor and deutivacaftor. FDA describes it as an oral medicine taken once daily. The components are CFTR modulators, medicines designed to improve the function of qualifying CFTR protein variants. They do not repair the underlying DNA mutation or cure cystic fibrosis. [1][2]
F508del is the most common disease-causing CFTR mutation and was named directly in the indication. The phrase another responsive mutation means a different variant must have evidence of response recognized in the approved label. It does not mean every rare or newly reported CFTR change automatically qualifies, and genetic test results need clinical interpretation. [1]
FDA based the original approval on evidence that included two phase 3 trials with 971 participants. The trials compared Alyftrek with the combination elexacaftor, tezacaftor and ivacaftor after a four-week run-in period. The main efficacy measure was change in percent-predicted FEV1, a standard lung-function measure, through 24 weeks. [1]
The pivotal comparative trials enrolled patients age 12 and older, even though the original indication began at age six. FDA's public snapshot makes both facts clear and should not be read as saying that six-year-olds were part of those two efficacy trial populations. The prescribing information and FDA review explain the evidence supporting each approved age and dose group. [1]
In the trials, Alyftrek was noninferior to the comparator regimen for the primary lung-function endpoint, meaning the study met a prespecified standard for being not unacceptably worse. Noninferiority does not mean every patient will respond equally or that the medicine is superior on all outcomes. Individual benefits, interactions, monitoring and adverse effects require clinician review. [1]
The practical answer is therefore genotype-specific. A person or caregiver should confirm the exact CFTR variants, age-appropriate formulation and current prescribing information with a cystic fibrosis specialist or pharmacist. FDA's Drug Trials Snapshot describes the original December 2024 decision and warns that it may not reflect later approvals, so it should not replace the current label or medical advice. [1][2]